The Goldman Sachs Group Cuts Kestra Medical Technologies (NASDAQ:KMTS) Price Target to $23.00

Kestra Medical Technologies (NASDAQ:KMTS) had its price objective decreased by analysts at The Goldman Sachs Group from $24.00 to $23.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential downside of 5.74% from the company’s previous close.

KMTS has been the topic of a number of other reports. Wells Fargo & Company began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an “overweight” rating and a $28.00 target price on the stock. Wolfe Research began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “outperform” rating and a $29.00 price target on the stock. Piper Sandler started coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They set an “overweight” rating and a $27.00 target price on the stock. Bank of America started coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They set a “buy” rating and a $28.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

Kestra Medical Technologies Stock Performance

KMTS traded up $0.27 during midday trading on Wednesday, reaching $24.40. 176,002 shares of the company’s stock were exchanged, compared to its average volume of 265,959. Kestra Medical Technologies has a 1-year low of $20.00 and a 1-year high of $26.15.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Monday, April 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same quarter in the prior year, the business earned ($1.18) EPS.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.